Roche suspends arthritis drug study after deaths

March 08, 2010 06:42 pm | Updated November 17, 2021 06:48 am IST - BASEL, Switzerland

Franz B. Humer, chairman of the board of Roche, speaks during the general assembly of Swiss pharmaceutical company Roche Holding AG, in Basel, Switzerland, last week. Photo: AP.

Franz B. Humer, chairman of the board of Roche, speaks during the general assembly of Swiss pharmaceutical company Roche Holding AG, in Basel, Switzerland, last week. Photo: AP.

Swiss pharmaceutical company Roche Group said on Monday it has suspended a late—stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections.

Roche said the drug, ocrelizumab, was developed together with Biogen Idec with headquarters in Cambridge, Massachusetts.

A review found “the safety risk outweighs the benefits observed in these specific patient populations at this time” after detecting “serious and opportunistic infections, some of which were fatal,” Basel—based Roche said.

It declined immediately to say how many patients died, where and when.

The company said it was still testing ocrelizumab for patients with relapsing remitting multiple sclerosis

Roche shares were down 0.6 percent at 179.60 Swiss francs ($167.54) on the Zurich exchange.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.